Skip to content

Methodological considerations for interpreting ketamine-naltrexone trials in depression

Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone, Boris D. Heifets, Carolyn I. Rodríguez, Alan F. Schatzberg

The International Journal of Neuropsychopharmacology October 1, 2025 DOI: 10.1093/ijnp/pyaf073 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Depression Esketamine Ketamine
Keywords Depression economics Medline Clinical trial Clinical neurology Clinical psychology
Citations 4
Key findings Argues that ketamine and esketamine show rapid antidepressant effects but that long-term safety and optimal treatment protocols require further investigation.

Abstract

Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD